Company Name, Ticker, Competitors, else..

Best Performing Stocks In Biotechnology & Pharmaceuticals Industry During The Previous 90 Days

1 Day

Week

Current Month of September

30 Days

Current Quarter Q3 of 2024

90 Days

Ytd

12 Months

Shares improved by 8.02% on average, in Biotechnology & Pharmaceuticals Industry during the previous 90 days.

Here are the best performing stocks in Biotechnology & Pharmaceuticals Industry.

SNTI

$3.07

$2.7813

963.39%
Last 90 Days

SNTI

$3.07

$2.7813

963.39%

Senti Biosciences Inc

Senti Biosciences Inc stock increased 963.39% during the previous 90 days.

Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 14.036 mill.	$ - mill.	$ -56.934 mill.	5 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 14.036 mill.	$ - mill.	$ -56.934 mill.
Employees	Shares Outstanding	P/E
-	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

FNCH

$11.3

$9.9100

712.95%
Last 90 Days

FNCH

$11.3

$9.9100

712.95%

Finch Therapeutics Group Inc

Finch Therapeutics Group Inc stock increased 712.95% during the previous 90 days.

Finch Therapeutics Group Inc*s business model revolves around developing microbiome-based therapies for various diseases and conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 18.136 mill.	$ - mill.	$ -100.313 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 18.136 mill.	$ - mill.	$ -100.313 mill.
Employees	Shares Outstanding	P/E
-	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TIL

$84.52

$73.6800

679.70%
Last 90 Days

TIL

$84.52

$73.6800

679.70%

Instil Bio Inc

Instil Bio Inc stock increased 679.70% during the previous 90 days.

Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 549.711 mill.	$ - mill.	$ -125.313 mill.	7 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 549.711 mill.	$ - mill.	$ -125.313 mill.
Employees	Shares Outstanding	P/E
-	7 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CLDI

$1.16

$0.8900

329.63%
Last 90 Days

CLDI

$1.16

$0.8900

329.63%

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc shares increased 329.63% during the previous 90 days.

Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 41.240 mill.	$ - mill.	$ -34.216 mill.	36 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 41.240 mill.	$ - mill.	$ -34.216 mill.
Employees	Shares Outstanding	P/E
-	36 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

BIEI

$0.0018

$0.0009

100.00%
Last 90 Days

BIEI

$0.0018

$0.0009

100.00%

Premier Biomedical Inc

Premier Biomedical Inc stock increased 100.00% during the previous 90 days.

Premier Biomedical Inc operates as a biotechnology company that develops and commercializes medical treatments for various diseases. Their business model focuses on researching, developing, and marketing novel therapies leveraging their proprietary technology and partnerships with healthcare providers and organizations.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.298 mill.	$ 0.014 mill.	$ -0.374 mill.	165 mill.	-	Y/Y -85.63 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.298 mill.	$ 0.014 mill.	$ -0.374 mill.
Employees	Shares Outstanding	P/E
-	165 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -85.63 %	MRQ Y/Y - %

ADMA

$18.09

$7.5900

72.29%
Last 90 Days

ADMA

$18.09

$7.5900

72.29%

Adma Biologics Inc

Adma Biologics Inc shares increased 72.29% during the previous 90 days.

Adma Biologics Inc operates as a biopharmaceutical company focused on producing and commercializing specialty plasma-derived biologics for various medical conditions. The company*s business model revolves around collecting and fractionating plasma from qualified donors to manufacture and sell therapies for immune deficiency disorders, autoimmune diseases, and other indications. Adma Biologics markets its products directly to healthcare providers, hospitals, and other healthcare institutions while prioritizing patient safety and product quality.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4,380.802 mill.	$ 328.899 mill.	$ 34.789 mill.	242 mill.	119.97	Y/Y 78.34 %

Market Cap.	Revenues TTM	Net Income TTM
$ 4,380.802 mill.	$ 328.899 mill.	$ 34.789 mill.
Employees	Shares Outstanding	P/E
256	242 mill.	119.97
Revenue Growth	Income Growth
MRQ Y/Y 78.34 %	MRQ Y/Y - %

SQZB

$0.0596

$0.0226

61.08%
Last 90 Days

SQZB

$0.0596

$0.0226

61.08%

Sqz Biotechnologies Company

Sqz Biotechnologies Company stock improved 61.08% during the previous 90 days.

Sqz Biotechnologies Company*s business model revolves around developing and commercializing innovative cell engineering platforms for multiple applications across the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.758 mill.	$ - mill.	$ 0.000 mill.	29 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.758 mill.	$ - mill.	$ 0.000 mill.
Employees	Shares Outstanding	P/E
-	29 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PCVX

$116

$43.4200

59.82%
Last 90 Days

PCVX

$116

$43.4200

59.82%

Vaxcyte Inc

Vaxcyte Inc shares increased 59.82% during the previous 90 days.

Vaxcyte Inc*s business model revolves around developing and commercializing vaccines to prevent diseases with a focus on advancing innovative approaches to address unmet medical needs. They aim to create value by leveraging their scientific expertise, conducting clinical studies, obtaining regulatory approvals, and efficiently manufacturing and distributing vaccines worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 13,601.761 mill.	$ - mill.	$ -384.726 mill.	117 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 13,601.761 mill.	$ - mill.	$ -384.726 mill.
Employees	Shares Outstanding	P/E
-	117 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

AVXL

$5.31

$1.6100

43.51%
Last 90 Days

AVXL

$5.31

$1.6100

43.51%

Anavex Life Sciences Corp

Anavex Life Sciences Corp shares went up 43.51% during the previous 90 days.

Anavex Life Sciences Corp*s business model focuses on the development and commercialization of innovative pharmaceutical products for the treatment of central nervous system diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 448.883 mill.	$ 1.788 mill.	$ -41.528 mill.	85 mill.	25.29	Y/Y -6.88 %

Market Cap.	Revenues TTM	Net Income TTM
$ 448.883 mill.	$ 1.788 mill.	$ -41.528 mill.
Employees	Shares Outstanding	P/E
-	85 mill.	25.29
Revenue Growth	Income Growth
MRQ Y/Y -6.88 %	MRQ Y/Y - %

ARGX

$538.01

$161.2200

42.79%
Last 90 Days

ARGX

$538.01

$161.2200

42.79%

Argenx se

Argenx Se shares improved 42.79% during the previous 90 days.

Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 30,757.630 mill.	$ 2,494.910 mill.	$ -295.053 mill.	57 mill.	-	Y/Y 191.46 %

Market Cap.	Revenues TTM	Net Income TTM
$ 30,757.630 mill.	$ 2,494.910 mill.	$ -295.053 mill.
Employees	Shares Outstanding	P/E
-	57 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 191.46 %	MRQ Y/Y - %

DNLI

$30.77

$9.1700

42.45%
Last 90 Days

DNLI

$30.77

$9.1700

42.45%

Denali Therapeutics Inc

Denali Therapeutics Inc shares went up 42.45% during the previous 90 days.

Denali Therapeutics Inc is a biotechnology company focused on developing and delivering effective therapies for neurodegenerative diseases. Their business model revolves around leveraging their deep knowledge of neurology and genetics to discover and develop innovative drugs. They aim to commercialize these therapies through strategic partnerships with pharmaceutical companies or through independent clinical development.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 5,194.940 mill.	$ - mill.	$ -457.843 mill.	169 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 5,194.940 mill.	$ - mill.	$ -457.843 mill.
Employees	Shares Outstanding	P/E
340	169 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ACLX

$76.89

$22.8900

42.39%
Last 90 Days

ACLX

$76.89

$22.8900

42.39%

Arcellx Inc

Arcellx Inc stock improved 42.39% during the previous 90 days.

Arcellx Inc operates on a business model focused on developing and commercializing next-generation cell therapies for the treatment of various diseases by utilizing its proprietary ARC-SparX platform technology. The company intends to leverage its technology to create novel and improved therapies, targeting both liquid and solid tumors, aiming for better patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3,724.405 mill.	$ 47.171 mill.	$ -129.526 mill.	48 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 3,724.405 mill.	$ 47.171 mill.	$ -129.526 mill.
Employees	Shares Outstanding	P/E
-	48 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

GLUE

$6.08

$1.8000

42.06%
Last 90 Days

GLUE

$6.08

$1.8000

42.06%

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc shares went up 42.06% during the previous 90 days.

Monte Rosa Therapeutics Inc operates under a specific business model that focuses on a unique approach in the field of therapeutics.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 302.875 mill.	$ - mill.	$ -132.882 mill.	50 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 302.875 mill.	$ - mill.	$ -132.882 mill.
Employees	Shares Outstanding	P/E
-	50 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

AURA

$10.07

$2.9300

41.04%
Last 90 Days

AURA

$10.07

$2.9300

41.04%

Aura Biosciences Inc

Aura Biosciences Inc stock went up 41.04% during the previous 90 days.

Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 384.525 mill.	$ - mill.	$ -70.836 mill.	38 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 384.525 mill.	$ - mill.	$ -70.836 mill.
Employees	Shares Outstanding	P/E
-	38 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SGMO

$0.8484

$0.2407

39.61%
Last 90 Days

SGMO

$0.8484

$0.2407

39.61%

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc shares went up 39.61% during the previous 90 days.

Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients* lives.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 173.028 mill.	$ 12.277 mill.	$ -249.675 mill.	204 mill.	-	Y/Y -94.79 %

Market Cap.	Revenues TTM	Net Income TTM
$ 173.028 mill.	$ 12.277 mill.	$ -249.675 mill.
Employees	Shares Outstanding	P/E
411	204 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -94.79 %	MRQ Y/Y - %

ALEC

$6.03

$1.6100

36.43%
Last 90 Days

ALEC

$6.03

$1.6100

36.43%

Alector Inc

Alector Inc shares went up 36.43% during the previous 90 days.

Alector Inc*s business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 506.086 mill.	$ 96.312 mill.	$ -141.385 mill.	84 mill.	-	Y/Y -38.67 %

Market Cap.	Revenues TTM	Net Income TTM
$ 506.086 mill.	$ 96.312 mill.	$ -141.385 mill.
Employees	Shares Outstanding	P/E
155	84 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -38.67 %	MRQ Y/Y - %

CMPX

$1.65

$0.4300

35.25%
Last 90 Days

CMPX

$1.65

$0.4300

35.25%

Compass Therapeutics Inc

Compass Therapeutics Inc shares improved 35.25% during the previous 90 days.

Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 227.022 mill.	$ 0.850 mill.	$ -47.242 mill.	138 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 227.022 mill.	$ 0.850 mill.	$ -47.242 mill.
Employees	Shares Outstanding	P/E
-	138 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ADPT

$4.61

$1.1600

33.62%
Last 90 Days

ADPT

$4.61

$1.1600

33.62%

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation shares went up 33.62% during the previous 90 days.

Adaptive Biotechnologies Corporation is a biotechnology company that utilizes its proprietary immune medicine platform to decode and analyze the human immune system. Their business model focuses on providing solutions for the diagnosis, monitoring, and treatment of various diseases such as cancer and infectious diseases. By leveraging genomics and machine learning technologies, they aim to create personalized immunotherapies and diagnostics to improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 667.089 mill.	$ 179.690 mill.	$ -196.006 mill.	145 mill.	-	Y/Y -20.72 %

Market Cap.	Revenues TTM	Net Income TTM
$ 667.089 mill.	$ 179.690 mill.	$ -196.006 mill.
Employees	Shares Outstanding	P/E
645	145 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -20.72 %	MRQ Y/Y - %

KYMR

$46.08

$11.5100

33.29%
Last 90 Days

KYMR

$46.08

$11.5100

33.29%

Kymera Therapeutics Inc

Kymera Therapeutics Inc stock increased 33.29% during the previous 90 days.

Kymera Therapeutics Inc is a biotechnology company that focuses on developing targeted protein degraders as potential therapeutic solutions. They utilize a proprietary technology platform to design and develop small molecules that can selectively degrade disease-causing proteins, aiming to treat various diseases including cancer and autoimmune disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2,692.079 mill.	$ 40.258 mill.	$ -175.596 mill.	58 mill.	-	Y/Y -58.94 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2,692.079 mill.	$ 40.258 mill.	$ -175.596 mill.
Employees	Shares Outstanding	P/E
-	58 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -58.94 %	MRQ Y/Y - %

CCCC

$6.44

$1.5800

32.51%
Last 90 Days

CCCC

$6.44

$1.5800

32.51%

C4 Therapeutics Inc

C4 Therapeutics Inc stock improved 32.51% during the previous 90 days.

C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid? platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body*s natural protein degradation machinery.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 443.138 mill.	$ 29.378 mill.	$ -107.868 mill.	69 mill.	-	Y/Y 350.68 %

Market Cap.	Revenues TTM	Net Income TTM
$ 443.138 mill.	$ 29.378 mill.	$ -107.868 mill.
Employees	Shares Outstanding	P/E
-	69 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 350.68 %	MRQ Y/Y - %

VXRT

$0.9871

$0.2176

28.28%
Last 90 Days

VXRT

$0.9871

$0.2176

28.28%

Vaxart Inc

Vaxart Inc stock went up 28.28% during the previous 90 days.

Vaxart Inc*s business model involves the development of oral vaccines through their proprietary tablet vaccine delivery platform.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 182.320 mill.	$ 13.928 mill.	$ -75.658 mill.	185 mill.	-	Y/Y 371.35 %

Market Cap.	Revenues TTM	Net Income TTM
$ 182.320 mill.	$ 13.928 mill.	$ -75.658 mill.
Employees	Shares Outstanding	P/E
-	185 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 371.35 %	MRQ Y/Y - %

GILD

$82.81

$17.9200

27.62%
Last 90 Days

GILD

$82.81

$17.9200

27.62%

Gilead Sciences Inc

Gilead Sciences Inc shares went up 27.62% during the previous 90 days.

Gilead Sciences Inc*s business model revolves around researching, developing, and commercializing innovative medicines in various therapeutic areas, with a primary focus on antiviral drugs. They aim to address unmet medical needs and improve the lives of patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 103,595.310 mill.	$ 27,805.000 mill.	$ 1,033.000 mill.	1,251 mill.	100.72	Y/Y 5.38 %

Market Cap.	Revenues TTM	Net Income TTM
$ 103,595.310 mill.	$ 27,805.000 mill.	$ 1,033.000 mill.
Employees	Shares Outstanding	P/E
17,000	1,251 mill.	100.72
Revenue Growth	Income Growth
MRQ Y/Y 5.38 %	MRQ Y/Y 55.34 %

CRGX

$22.17

$4.7500

27.27%
Last 90 Days

CRGX

$22.17

$4.7500

27.27%

Cargo Therapeutics Inc

Cargo Therapeutics Inc shares increased 27.27% during the previous 90 days.

Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 16.602 mill.	$ - mill.	$ -616.471 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 16.602 mill.	$ - mill.	$ -616.471 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

BNTX

$123.4

$24.6000

24.90%
Last 90 Days

BNTX

$123.4

$24.6000

24.90%

Biontech Se

Biontech Se shares improved 24.90% during the previous 90 days.

Biontech SE*s business model focuses on the development and commercialization of novel mRNA-based immunotherapies for various diseases, including cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 29,973.634 mill.	$ 4,277.280 mill.	$ 1,041.936 mill.	243 mill.	28.77	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 29,973.634 mill.	$ 4,277.280 mill.	$ 1,041.936 mill.
Employees	Shares Outstanding	P/E
1,700	243 mill.	28.77
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y -90.14 %

HALO

$62.3

$12.3800

24.80%
Last 90 Days

HALO

$62.3

$12.3800

24.80%

Halozyme Therapeutics Inc

Halozyme Therapeutics Inc shares increased 24.80% during the previous 90 days.

Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 8,050.531 mill.	$ 873.304 mill.	$ 337.293 mill.	129 mill.	24.04	Y/Y 4.67 %

Market Cap.	Revenues TTM	Net Income TTM
$ 8,050.531 mill.	$ 873.304 mill.	$ 337.293 mill.
Employees	Shares Outstanding	P/E
3,011	129 mill.	24.04
Revenue Growth	Income Growth
MRQ Y/Y 4.67 %	MRQ Y/Y 24.74 %

SCNI

$3.4359

$0.6759

24.49%
Last 90 Days

SCNI

$3.4359

$0.6759

24.49%

Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd shares went up 24.49% during the previous 90 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 5,369.032 mill.	$ - mill.	$ 6.500 mill.	1,563 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 5,369.032 mill.	$ - mill.	$ 6.500 mill.
Employees	Shares Outstanding	P/E
-	1,563 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y 0.00 %

REPL

$11.13

$2.1300

23.67%
Last 90 Days

REPL

$11.13

$2.1300

23.67%

Replimune Group Inc

Replimune Group Inc stock improved 23.67% during the previous 90 days.

Replimune Group Inc has a business model centered around the development of oncolytic immunotherapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 770.039 mill.	$ - mill.	$ -220.011 mill.	69 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 770.039 mill.	$ - mill.	$ -220.011 mill.
Employees	Shares Outstanding	P/E
-	69 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TRML

$19.27

$3.6500

23.37%
Last 90 Days

TRML

$19.27

$3.6500

23.37%

Tourmaline Bio Inc

Tourmaline Bio Inc shares went up 23.37% during the previous 90 days.

Tourmaline Bio Inc*s business model revolves around the development and commercialization of innovative healthcare solutions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 495.701 mill.	$ - mill.	$ -35.687 mill.	26 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 495.701 mill.	$ - mill.	$ -35.687 mill.
Employees	Shares Outstanding	P/E
-	26 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

BCRX

$7.92

$1.4400

22.22%
Last 90 Days

BCRX

$7.92

$1.4400

22.22%

Biocryst Pharmaceuticals Inc

Biocryst Pharmaceuticals Inc stock increased 22.22% during the previous 90 days.

Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1,634.886 mill.	$ 382.236 mill.	$ -145.933 mill.	206 mill.	-	Y/Y 32.54 %

Market Cap.	Revenues TTM	Net Income TTM
$ 1,634.886 mill.	$ 382.236 mill.	$ -145.933 mill.
Employees	Shares Outstanding	P/E
192	206 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 32.54 %	MRQ Y/Y - %

ESLA

$1.09

$0.1950

21.79%
Last 90 Days

ESLA

$1.09

$0.1950

21.79%

stock went up 21.79% during the previous 90 days.

Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 38.716 mill.	$ - mill.	$ -4.927 mill.	36 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 38.716 mill.	$ - mill.	$ -4.927 mill.
Employees	Shares Outstanding	P/E
-	36 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

NMRA

$12.03

$2.1400

21.64%
Last 90 Days

NMRA

$12.03

$2.1400

21.64%

Neumora Therapeutics Inc

Neumora Therapeutics Inc stock increased 21.64% during the previous 90 days.

Neumora Therapeutics Inc*s business model focuses on developing and commercializing novel therapeutic solutions in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 561.693 mill.	$ - mill.	$ -57.015 mill.	47 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 561.693 mill.	$ - mill.	$ -57.015 mill.
Employees	Shares Outstanding	P/E
-	47 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

EXEL

$26.46

$4.4300

20.11%
Last 90 Days

EXEL

$26.46

$4.4300

20.11%

Exelixis Inc

Exelixis Inc stock increased 20.11% during the previous 90 days.

Exelixis Inc*s business model is focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7,778.552 mill.	$ 2,013.976 mill.	$ 800.961 mill.	294 mill.	22.67	Y/Y 35.61 %

Market Cap.	Revenues TTM	Net Income TTM
$ 7,778.552 mill.	$ 2,013.976 mill.	$ 800.961 mill.
Employees	Shares Outstanding	P/E
566	294 mill.	22.67
Revenue Growth	Income Growth
MRQ Y/Y 35.61 %	MRQ Y/Y 185.83 %

IOVA

$10.34

$1.7200

19.95%
Last 90 Days

IOVA

$10.34

$1.7200

19.95%

Iovance Biotherapeutics inc

Iovance Biotherapeutics Inc shares increased 19.95% during the previous 90 days.

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient*s own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2,945.008 mill.	$ 32.772 mill.	$ -440.216 mill.	285 mill.	-	Y/Y 12,969.75 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2,945.008 mill.	$ 32.772 mill.	$ -440.216 mill.
Employees	Shares Outstanding	P/E
-	285 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 12,969.75 %	MRQ Y/Y - %

GNTA

$3.95

$0.6500

19.70%
Last 90 Days

GNTA

$3.95

$0.6500

19.70%

Genenta Science S p a

Genenta Science S P A stock increased 19.70% during the previous 90 days.

Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 71.957 mill.	$ - mill.	$ -13.043 mill.	18 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 71.957 mill.	$ - mill.	$ -13.043 mill.
Employees	Shares Outstanding	P/E
-	18 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

APGE

$51.38

$8.1700

18.91%
Last 90 Days

APGE

$51.38

$8.1700

18.91%

Apogee Therapeutics inc

Apogee Therapeutics Inc stock went up 18.91% during the previous 90 days.

Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2,578.752 mill.	$ - mill.	$ -71.819 mill.	50 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 2,578.752 mill.	$ - mill.	$ -71.819 mill.
Employees	Shares Outstanding	P/E
-	50 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IMVT

$29.67

$4.5700

18.21%
Last 90 Days

IMVT

$29.67

$4.5700

18.21%

Immunovant Inc

Immunovant Inc shares improved 18.21% during the previous 90 days.

Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4,334.364 mill.	$ - mill.	$ -272.549 mill.	146 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 4,334.364 mill.	$ - mill.	$ -272.549 mill.
Employees	Shares Outstanding	P/E
-	146 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

STRO

$4.5

$0.6800

17.80%
Last 90 Days

STRO

$4.5

$0.6800

17.80%

Sutro Biopharma Inc

Sutro Biopharma Inc stock went up 17.80% during the previous 90 days.

Sutro Biopharma Inc has a business model focused on developing and commercializing innovative antibody-based therapeutics.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 272.696 mill.	$ 48.642 mill.	$ -172.452 mill.	61 mill.	-	Y/Y -32.70 %

Market Cap.	Revenues TTM	Net Income TTM
$ 272.696 mill.	$ 48.642 mill.	$ -172.452 mill.
Employees	Shares Outstanding	P/E
-	61 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -32.70 %	MRQ Y/Y - %

ALLO

$2.96

$0.4100

16.08%
Last 90 Days

ALLO

$2.96

$0.4100

16.08%

Allogene Therapeutics Inc

Allogene Therapeutics Inc shares went up 16.08% during the previous 90 days.

Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 562.479 mill.	$ - mill.	$ -281.930 mill.	190 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 562.479 mill.	$ - mill.	$ -281.930 mill.
Employees	Shares Outstanding	P/E
-	190 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

LENZ

$21.86

$2.8900

15.23%
Last 90 Days

LENZ

$21.86

$2.8900

15.23%

Lenz Therapeutics Inc

Lenz Therapeutics Inc shares improved 15.23% during the previous 90 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 559.804 mill.	$ - mill.	$ -104.701 mill.	26 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 559.804 mill.	$ - mill.	$ -104.701 mill.
Employees	Shares Outstanding	P/E
-	26 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ALGS

$14.8

$1.7750

13.63%
Last 90 Days

ALGS

$14.8

$1.7750

13.63%

Aligos Therapeutics Inc

Aligos Therapeutics Inc shares went up 13.63% during the previous 90 days.

Aligos Therapeutics Inc*s business model involves developing innovative therapeutics for the treatment of viral diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 643.755 mill.	$ 16.385 mill.	$ -81.673 mill.	44 mill.	-	Y/Y -21.12 %

Market Cap.	Revenues TTM	Net Income TTM
$ 643.755 mill.	$ 16.385 mill.	$ -81.673 mill.
Employees	Shares Outstanding	P/E
-	44 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -21.12 %	MRQ Y/Y - %